Phase 2 N=73 Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer
Lung Cancer · Adenocarcinoma
Primary: Phase I: Recommend Phase II Dose (RPDII) — 1 Recommend Phase II Dose Level
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 A Prospective Comparison of Ultrasound-Guided Percutaneous Platelet-Rich Plasma Injection
Tendinosis · Tendinitis
Primary: Pain Level and Interference With Activity — 16.8; 25.5; 15.2; 19.4 units on a scale — p=<0.0001
Phase 3 N=569 Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
HER2/Neu Over-expressing Locally Advanced Breast Cancer · Metastatic Breast Cancer
Primary: Progressive-free Survival (PFS) Per Investigator Assessment — 7.00; 5.78 months — p=0.0067
N/A N=181 The Effects of Obesity and Obstructive Sleep Apnea on Inflammation and Heart Disease
Sleep Apnea Syndromes · Inflammation
Primary: Inflammation — -11.47; -37.45; -32.66 percentage of change in crp at week 24
Phase 2 N=51 Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
Pancreatic Cancer
Primary: One Year Survival Rate — 0.502 proportion of patients
Phase 3 N=625 Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain
Low Back Pain
Primary: Change From Baseline to Week 12 of the Treatment Period in Weekly Average of Daily Worst Pain Intensity (WPI) — 0.71; 0.07 units on a scale — p=<0.001
Phase 2 N=150 ABT-436 for Alcohol Dependence
Alcohol Dependence · Alcohol Abuse · Alcohol Use Disorders
Primary: Weekly Percentage of Heaving Drinking Days — 37.6; 31.3 weekly percentage of heavy drinking days
Phase 3 N=564 S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo
Breast Cancer
Primary: Overall Survival — 10.7; 12.5 months — p=0.98
N/A N=18 Image Guided Adaptive Radiotherapy in the Head-and-neck Region
Head and Neck Neoplasms
Primary: Planning Target Volume (PTV) Coverage Parameter D98% — 7 participants
N/A N=120 PTSD Coach App Evaluation
PTSD
Primary: Change in PTSD Symptoms Measured by the Post Traumatic Stress Disorder Checklist (PCL) — 63.19; 60.59; 51.93; 53.90 units on a scale — p=.035
Phase 3 N=738 Long-term Oxygen Treatment Trial
Chronic Obstructive Pulmonary Disease
Primary: Death or Hospitalization, Whichever Occurs First — 34.2; 36.4 Composite events/100 person-years — p=0.52
Phase 4 N=87 PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
Hemophilia A
Primary: Percentage of Participants With Factor VIII (FVIII) Inhibitors — 8.22; 7.14 percentage of participants
N/A N=18 The Effect of Omalizumab on Responses to Cat Allergen Challenge
Allergic Rhinitis
Primary: Change in Basophil Surface IgE — -95; -10 percentage of basophil surface IgE
Phase 3 N=8,094 S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000
Colorectal Cancer · Precancerous Condition
Primary: Effect of Selenium on Colorectal Adenoma (CRA) Occurrence, Analyzed by Active Selenium vs. Selenium Placebo — 1136; 1150 Participants — p=0.96
Phase 2 N=32 Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer
Lung Cancer
Primary: Number of Participants Showing Immunologic Response to Vaccine Within Six Months of Immunization — 22 participants with immunological response